Nano-delivery systems of nucleic acid drugs for osteoarthritis therapy
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Osteoarthritis Treatment and Mechanisms · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Prevalence trends of site-specific osteoarthritis from 1990 to 2019: findings from the global burden of disease study 201910.1002/art.42089 ↗
2. Nanomedicines reprogram synovial macrophages by scavenging nitric oxide and silencing CA9 in progressive osteoarthritis10.1002/advs.202207490 ↗
3. Association between metabolic syndrome and knee structural change on MRI
4. Clinical aspects and outcomes in osteoarthritis
5. Pain and affective distress in arthritis: relationship to immunity and inflammation10.1080/1744666X.2019.1573675 ↗
6. Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis10.1136/bmj.n2321 ↗
7. Risk of periprosthetic joint infection after intra-articular injection: any difference among shoulder, knee and hip?10.3390/healthcare12111060 ↗
8. Infection risk increases after total hip arthroplasty within 3 months following intra-articular corticosteroid injection. A meta-analysis on knee and hip arthroplasty10.1016/j.arth.2022.12.038 ↗
9. Intra-articular hyaluronic acid for knee osteoarthritis: a systematic umbrella review10.3390/jcm14041272 ↗
10. Nanotechnology-boosted biomaterials for osteoarthritis treatment: current status and future perspectives10.2147/IJN.S423737 ↗
11. Efficacy of intra-articular injections for the treatment of osteoarthritis: a narrative review
12. Schrama · Arthritis Care Res · 2010 · 62 · 47310.1002/acr.20036 ↗
13. miR 155 5p regulates macrophage M1 polarization and apoptosis in the synovial fluid of patients with knee osteoarthritis10.3892/etm.2020.9500 ↗
14. Targeting cellular senescence as a novel treatment for osteoarthritis10.1016/j.coph.2022.102213 ↗
15. Mechanisms and targets of angiogenesis and nerve growth in osteoarthritis10.1038/nrrheum.2012.80 ↗
16. Engineering approaches for RNA-based and cell-based osteoarthritis therapies10.1038/s41584-023-01067-4 ↗
17. Osteoarthritis gene therapy in 202210.1097/BOR.0000000000000918 ↗
18. New treatment for osteoarthritis: gene therapy10.1093/pcmedi/pbad014 ↗
19. Nanodelivery of nucleic acids10.1038/s43586-022-00104-y ↗
20. Drug delivery systems for RNA therapeutics10.1038/s41576-021-00439-4 ↗
21. Construction of nanocarriers based on nucleic acids and their applications in nanobiology delivery systems10.1093/nsr/nwac006 ↗
22. Nucleic acid-based nanogels for drug delivery: from construction strategies to intelligent applications10.1016/j.colsurfb.2025.114948 ↗
23. RNA-targeting techniques: a comparative analysis of modern approaches for RNA manipulation in cancer research and therapeutics10.3390/genes16101168 ↗
24. Nucleic acid aptamers in orthopedic diseases: promising therapeutic agents for bone disorders10.1038/s41413-025-00447-8 ↗
25. Amelioration of osteoarthritis via tetrahedral framework nucleic acids delivering MicroRNA-124 for cartilage regeneration10.1002/adfm.202305558 ↗
26. MicroRNAs in action: biogenesis, function and regulation10.1038/s41576-023-00611-y ↗
27. MiR-335-5p escaped from CircKIAA0586 adsorption contributes to mechanical overloading-induced cartilage degeneration by targeting lymphoid-specific helicase10.34133/research.0694 ↗
28. LncRNA PVT1 regulates chondrocyte proliferation and apoptosis through the glycolysis process mediated by miR-552-3p/PKM2 to promote osteoarthritis10.1007/s11626-025-01090-7 ↗
29. Dual functions of microRNA-17 in maintaining cartilage homeostasis and protection against osteoarthritis10.1038/s41467-022-30119-8 ↗
30. Engineering exosomes derived from subcutaneous fat MSCs specially promote cartilage repair as miR-199a-3p delivery vehicles in osteoarthritis10.1186/s12951-023-02086-9 ↗
31. Mechanosensitive miRNAs in cartilage and subchondral bone remodeling: emerging targets for osteoarthritis therapy10.2147/JIR.S529149 ↗
32. M2 macrophage-derived exosomal miR-26b-5p regulates macrophage polarization and chondrocyte hypertrophy by targeting TLR3 and COL10A1 to alleviate osteoarthritis10.1186/s12951-024-02336-4 ↗
33. Unlocking the promise of mRNA therapeutics10.1038/s41587-022-01491-z ↗
34. Charge-assisted stabilization of lipid nanoparticles enables inhaled mRNA delivery for mucosal vaccination10.1038/s41467-024-53914-x ↗
35. Atavistic strategy for the treatment of hyperuricemia via ionizable liposomal mRNA10.1038/s41467-024-50752-9 ↗
36. RNA nanotherapeutics with fibrosis overexpression and retention for MASH treatment10.1038/s41467-024-51571-8 ↗
37. Runx1 alleviates osteoarthritis progression in aging mice10.1080/01478885.2023.2281790 ↗
38. Anti-inflammatory therapy for temporomandibular joint osteoarthritis using mRNA medicine encoding interleukin-1 receptor antagonist10.3390/pharmaceutics14091785 ↗
39. Therapeutic siRNA: state of the art10.1038/s41392-020-0207-x ↗
40. Targeting of hyperlipid-producing senescent synovial fibroblasts to ameliorate cartilage degeneration10.1073/pnas.2417708122 ↗
41. A pH-responsive metal-organic framework for the co-delivery of HIF-2α siRNA and curcumin for enhanced therapy of osteoarthritis10.1186/s12951-022-01758-2 ↗
42. siRNA therapy in osteoarthritis: targeting cellular pathways for advanced treatment approaches
43. MicroRNA-199-3p up-regulation enhances chondrocyte proliferation and inhibits apoptosis in knee osteoarthritis via DNMT3A repression10.1007/s00011-020-01430-1 ↗
44. Mechanisms and therapeutic implications of gene expression regulation by circRNA-protein interactions in cancer10.1038/s42003-024-07383-z ↗
45. Circular RNAs as key regulators in cancer hallmarks: New progress and therapeutic opportunities10.1016/j.critrevonc.2024.104612 ↗
46. CircRNAs in osteoarthritis: research status and prospect
47. New perspectives on the roles of circular RNAs in osteoarthritis development and progression (Review)10.3892/etm.2021.10906 ↗
48. CircFOXO3 protects against osteoarthritis by targeting its parental gene FOXO3 and activating PI3K/AKT-mediated autophagy10.1038/s41419-022-05390-8 ↗
49. Circular RNA-based protein replacement therapy mitigates osteoarthritis in male mice10.1038/s41467-025-63343-z ↗
50. Emerging technology has a brilliant future: the CRISPR-Cas system for senescence, inflammation, and cartilage repair in osteoarthritis10.1186/s11658-024-00581-x ↗
51. Applications of CRISPR technologies in research and beyond10.1038/nbt.3659 ↗
52. Advances in CRISPR therapeutics10.1038/s41581-022-00636-2 ↗
53. CRISPR/CasRx-mediated RNA knockdown targeting β-catenin and Ihh signaling alleviates osteoarthritis
54. Targeted S100A8 PP-Cas9@PLGA-apt microparticles reduced cartilage degradation and subchondral bone isomerism in osteoarthritis treatment through JAK/STAT3 pathway modulation
55. Development of injectable aldehyde hyaluronic acid hydrogels loaded with CRISPRa reprogrammed elite macrophages for the treatment of osteoarthritis10.1021/acsami.5c04355 ↗
56. Topological switch-OFF and β-galactosidase-triggered switch-ON of cyclic antisense oligonucleotides via CuAAC for controlled RNA cleavage10.1021/acs.bioconjchem.5c00295 ↗
57. Antisense oligonucleotides as drugs with both direct and indirect antiviral actions10.1016/j.antiviral.2025.106219 ↗
58. Designing nucleic acid-based therapeutics for cancer treatment: updates on the state of the art
59. Translational and clinical development of therapeutic siRNA and ASOs: current industry practices, perspectives, and recommendations10.1093/nar/gkaf778 ↗
60. Therapeutic antisense oligonucleotides are coming of age10.1146/annurev-med-041217-010829 ↗
61. A novel metal-organic framework encapsulated iridium oxide nanozyme enhanced antisense oligonucleotide combo for osteoarthritis synergistic therapy10.1002/agt2.635 ↗
62. Antisense oligonucleotide-based therapies for the treatment of osteoarthritis: opportunities and roadblocks10.1016/j.bone.2020.115461 ↗
63. Chondrocyte-targeted delivery system of Sortase A-engineered extracellular vesicles silencing MMP13 for osteoarthritis therapy10.1002/adhm.202303510 ↗
64. microRNA-181a-5p antisense oligonucleotides attenuate osteoarthritis in facet and knee joints10.1136/annrheumdis-2018-213629 ↗
65. Three decades of nucleic acid aptamer technologies: lessons learned, progress and opportunities on aptamer development10.1016/j.biotechadv.2018.11.001 ↗
66. Review of microchip analytical methods coupled with aptamer-based signal amplification strategies for high-sensitivity bioanalytical applications10.3390/bios15100653 ↗
67. Aptamers as a new frontier in targeted cancer therapy10.1016/j.addr.2025.115692 ↗
68. Characterisation of binding kinetics for vascular endothelial growth factor with self-assembled DNA aptamer using total internal reflection ellipsometry
69. Selection and characterization of DNA aptamers inhibiting a druggable target of osteoarthritis, ADAMTS-510.1016/j.biochi.2022.06.001 ↗
70. Antibody and aptamer-based therapies for osteoarthritis: Application of antibodies and promise of aptamers10.1016/j.omtn.2025.102552 ↗
71. Can CD200R1 agonists slow the progression of osteoarthritis secondary to injury?10.3389/fimmu.2022.836837 ↗
72. Therapeutic circRNA aptamer alleviates PKR-associated osteoarthritis10.1016/j.scib.2025.02.027 ↗
73. A plasmid system with tunable copy number10.1038/s41467-022-31422-0 ↗
74. Harnessing nucleic acids nanotechnology for bone/cartilage regeneration
75. Targeted interleukin-10 plasmid DNA therapy in the treatment of osteoarthritis: Toxicology and pain efficacy assessments10.1016/j.bbi.2020.08.005 ↗
76. Efficacy of P62-expressing plasmid in treatment of canine osteoarthritis pain: a pilot study10.3389/fvets.2025.1519881 ↗
77. Attenuation of osteoarthritis progression via locoregional delivery of Klotho-expressing plasmid DNA and Tanshinon IIA through a stem cell-homing hydrogel10.1186/s12951-024-02608-z ↗
78. Cleavage of structured RNAs is accelerated by high affinity DNAzyme agents10.1002/cbic.202400950 ↗
79. Endogenously triggered DNAzyme-based nanostructures for gene-combined therapy10.1002/anbr.202500044 ↗
80. Self-adaptive activation of DNAzyme nanoassembly for synergistically combined gene therapy
81. Self-supported DNA hydrogel facilitates microenvironment remodeling and cartilage repair to prevent osteoarthritis progression via an ambidextrous strategy10.1016/j.biomaterials.2025.123595 ↗
82. MicroRNA in osteoarthritis: physiopathology, diagnosis and therapeutic challenge10.1093/bmb/ldz015 ↗
83. The mRNA-based innovative strategy: progress and challenges
84. DNAzymes: expanding the potential of nucleic acid therapeutics10.1089/nat.2022.0066 ↗
85. Aptamers as targeted therapeutics: current potential and challenges10.1038/nrd.2016.199 ↗
86. Lipid nanoparticles for mRNA delivery10.1038/s41578-021-00358-0 ↗
87. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability10.1016/j.ijpharm.2021.120586 ↗
88. Boosting RNA nanotherapeutics with V-ATPase activating non-inflammatory lipid nanoparticles to treat chronic lung injury10.1038/s41467-025-61688-z ↗
89. Targeted Therapy of Osteoarthritis via Intra-Articular Delivery of Lipid-nanoparticle-encapsulated recombinant human FGF18 mRNA10.1002/adhm.202400804 ↗
90. Optimized lipid nanoparticle-mediated mRNA co-delivery of SOX5/SOX9 enables synergistic senescence reversal for osteoarthritis therapy10.2147/IJN.S544168 ↗
91. Cartilage-targeting mRNA-lipid nanoparticles rescue perifocal apoptotic chondrocytes for integrative cartilage repair10.1016/j.cej.2023.142841 ↗
92. Targeting FAP-positive chondrocytes in osteoarthritis: a novel lipid nanoparticle siRNA approach to mitigate cartilage degeneration10.1186/s12951-024-02946-y ↗
93. Dual-targeted lipid nanoparticles system for synergistic anti-inflammation and cartilage repair in the treatment of temporomandibular joint osteoarthritis10.1016/j.cej.2024.148769 ↗
94. Recent advancements in liposome technology10.1016/j.addr.2020.06.022 ↗
95. Intra-articular injection of lornoxicam and microRNA-140 co-loaded cationic liposomes enhanced the therapeutic treatment of experimental osteoarthritis10.1208/s12249-021-02149-w ↗
96. Polymeric delivery of therapeutic nucleic acids10.1021/acs.chemrev.0c00997 ↗
97. MicroRNA-224-5p nanoparticles balance homeostasis via inhibiting cartilage degeneration and synovial inflammation for synergistic alleviation of osteoarthritis10.1016/j.actbio.2023.06.010 ↗
98. Top-down fabricated microplates for prolonged, intra-articular matrix metalloproteinase 13 siRNA nanocarrier delivery to reduce post-traumatic osteoarthritis10.1021/acsnano.1c04005 ↗
99. Amelioration of post-traumatic osteoarthritis via nanoparticle depots delivering small interfering RNA to damaged cartilage10.1038/s41551-021-00780-3 ↗
100. Co-polymer carrier with dual advantages of cartilage-penetrating and targeting improves delivery and efficacy of microRNA treatment of osteoarthritis